Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs Macy's Inc (M) Price & Performance

Amylx Pharmaceuticals IncTrade
Macy's IncTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs Macy's Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.91 (market cap $2.64B), while Macy's Inc trades at $23.77 (market cap $6.45B). The key difference: Macy's Inc is far larger — about 2.4× Amylx Pharmaceuticals Inc's market cap, and Macy's Inc pays a 3.12% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AMLXM
Market Cap
$2.64B$6.45B
Sector
HealthConsumer Cyclical
52-Week High
$24.19$26.21
52-Week Low
$7.82$12.73
Enterprise Value
$2.39B$10.26B
Dividend Yield
3.12%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.

Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.

Macy's Inc

Macy's (M) trades at $24.9, down 1.97% on the day, with a bullish technical signal and strong earnings beat history. The company shows improving fundamentals with net income margin recovery to 2.94% and positive cash flow trends. Recent institutional buying and analyst coverage reflects growing confidence in the turnaround strategy, though revenue declines remain a concern.

The stock presents value opportunity with attractive valuation multiples (P/E 10.13, P/S 0.3) and dividend yield. Upside potential exists to the $30 analyst target, but risks include ongoing revenue pressure and competitive retail environment. The successful execution of 'Bold New Chapter' strategy remains critical for sustained recovery.

Returns comparison

Trailing returns across standard periods

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About Macy's Inc

Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.

Read more on M